Cathy Klema Net Worth

The estimated Net Worth of Cathy Klema is at least 365 千$ dollars as of 6 August 2013. Cathy Klema owns over 1,667 units of OptimizeRx Corp stock worth over 142,746$ and over the last 12 years Cathy sold OPRX stock worth over 221,761$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Cathy Klema OPRX stock SEC Form 4 insiders trading

Cathy has made over 1 trades of the OptimizeRx Corp stock since 2013, according to the Form 4 filled with the SEC. Most recently Cathy sold 1,667 units of OPRX stock worth 221,761$ on 6 August 2013.

The largest trade Cathy's ever made was selling 1,667 units of OptimizeRx Corp stock on 6 August 2013 worth over 221,761$. On average, Cathy trades about 152 units every 0 days since 2013. As of 6 August 2013 Cathy still owns at least 19,608 units of OptimizeRx Corp stock.

You can see the complete history of Cathy Klema stock trades at the bottom of the page.

What's Cathy Klema's mailing address?

Cathy's mailing address filed with the SEC is C/O OPTIMIZERX CORPORATION, 260 CHARLES STREET, SUITE 302, WALTHAM, MA, 02459.

Insiders trading at OptimizeRx Corp

Over the last 2001 years, insiders at OptimizeRx Corp have traded over 20,012,815$ worth of OptimizeRx Corp stock and bought 258,753 units worth 1,128,145$ . The most active insiders traders include Investment Company, Inc. Awm、Bradley Louis Radoff、David Harrell. On average, OptimizeRx Corp executives and independent directors trade stock every 32 days with the average trade being worth of 183,485$. The most recent stock trade was executed by Patrick D Spangler on 5 June 2024, trading 10,061 units of OPRX stock currently worth 73,244$.

What does OptimizeRx Corp do?

optimizerx partners with pharmaceutical companies to offer electronic versions of their patient savings and support materials within the eprescribing workflow of leading electronic health record platforms. using the samplemd technology, providers can more efficiently distribute savings and support materials to their patients. the ecoupon technology, available in the eprescribing workflow of over 300,000+ providers, has expanded the distribution of savings and support materials to millions of patients throughout the us and aims to increase adherence rates and affordability of prescribed medications. about optimizerx corp. optimizerx corp. provides unique consumer and physician platforms to help patients better afford and comply with their medications, while offering pharmaceutical companies effective ways to expand awareness, affordability and adherence to their brands. for more information on samplemd, please call us at (877) 568-3840 or visit www.samplemd.com.

Complete history of Cathy Klema stock trades at Enact Inc、OptimizeRx Corp

OptimizeRx Corp executives and stock owners

OptimizeRx Corp executives and other stock owners filed with the SEC include:

• Stephen Silvestro,
  Chief Commercial Officer
• William Febbo,
  Chief Executive Officer, Director
• William J. Febbo,
  CEO & Director
• Stephen L. Silvestro,
  Chief Commercial Officer
• Miriam Paramore,
  President
• Douglas Baker,
  Chief Financial Officer
• Gus Halas,
  Chairman of the Board
• Lynn Vos,
  Independent Director
• Patrick Spangler,
  Independent Director
• James Lang,
  Independent Director
• Angelo Campano,
  Senior Vice President - Principal of Agency Channels
• Ron Both,
  Investor Relations
• Gregory Wasson,
  Director
• Todd Inman,
  Chief Technology Officer
• Maira Alejandra,
  Media Relations Mang.
• Todd Inman,
  Chief Technology Officer
• Andrew Jacob D'Silva,
  Sr. VP of Corp. Fin.
• Douglas P. Baker,
  Exec. VP of Fin. & Accounting
• Edward Stelmakh C.M.A., M.B.A., MBA,
  CFO & COO
• Rebecca Whitney,
  Sr. VP of Commercial Operations
• Terence J. Hamilton,
  Sr. VP of Pharma
• Sheryl Kearney,
  HR Mang.
• Marion K Odence-Ford,
  Gen. Counsel & Chief Compliance Officer
• Cathy Klema,
  Director
• Ellen O'connor Vos,
  Director
• Plc Wpp Luxembourg Gamma Th...,
  
• Investment Company, Inc. Awm,
  10% owner
• Bradley Louis Radoff,
  10% owner
• Jack T Pinney,
  Director
• Richard Kraniak,
  10% owner
• David Lester,
  Chairman of the Board
• David Harrell,
  Chief Executive Officer
• Terrence Hamilton,
  Vice President
• James M Brooks,
  SVP of Business Development
• Brian J Dillon,
  SR. VP OF PRODUCT & STRATEGY
• Brian Clark Mc Carthy,
  Chief Revenue Officer
• Marion Odence Ford,
  General Counsel and CCO
• Edward Stelmakh,
  CFO/COO
• Doug Besch,
  Chief Product Officer
• Theresa Greco,
  Chief Commercial Officer